Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anzurstobart
- Development stage
- Discontinued
- Lead developer
- Bristol Myers Squibb
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Anzurstobart (CC-95251) is a humanized monoclonal antibody targeting Signal Regulatory Protein alpha (SIRPα), developed by Celgene (a subsidiary of Bristol Myers Squibb). SIRPα is an inhibitory receptor expressed on myeloid cells, including macrophages and dendritic cells. By binding to SIRPα, anzurstobart disrupts its interaction with CD47, a protein often overexpressed on cancer cells that sends a "don't eat me" signal to immune cells. This blockade promotes the phagocytosis of tumor cells by macrophages and enhances the adaptive immune response. It is being investigated as a monotherapy and in combination with other agents like cetuximab or rituximab for the treatment of advanced solid tumors (such as colorectal cancer and squamous cell carcinoma of the head and neck) and hematologic malignancies (including diffuse large B-cell lymphoma and follicular lymphoma).
- Brand names
- Anzurstobart
- Other names
- anzurstobart
02
Targets
SIRPA (Signal-regulatory protein alpha)
Beyond the preview
Go deeper on anzurstobart.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anzurstobart.